LENZ Therapeutics Q1 revenue rises on VIZZ launch

LENZ Therapeutics

11/05/2026 21:28

Overview

US presbyopia drugmaker's Q1 revenue reached $1.9 mln, driven by VIZZ product launch

Net loss widened to $41.5 mln as operating expenses rose with launch investments

Company expanded sales force and launched DTC campaign to boost VIZZ adoption

Outlook

LENZ expects expanded sales force to be fully deployed by end of Q2 2026

Company anticipates sales and marketing activities to drive further adoption of VIZZ

LENZ continues to pursue international partnerships and regulatory approvals for VIZZ

Result Drivers

VIZZ LAUNCH - Initial commercial launch of VIZZ drove Q1 product revenue, with about 25,000 paid prescriptions filled in the period

ECP UPTAKE - Broad uptake among eye care professionals, with over 10,000 unique prescribers from launch through Q1 2026

LAUNCH INVESTMENT - Higher SG&A expenses driven by launch-related marketing, advertising, sales infrastructure, and personnel costs

Company press release: ID:nGNX6H0xj3

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$41.49 mln
Q1 Income from Operations
-$44.14 mln
Q1 Operating Expenses
$46.04 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for LENZ Therapeutics Inc is $34.00, about 238% above its May 8 closing price of $10.06

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)